Jane Street
CRSP icon

Jane Street’s CRISPR Therapeutics CRSP Stock Holding History

Jane Street’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Sell
252,100
-91,100
-27% -$4.8M ﹤0.01% 2315
2025
Q4 		$18M Buy
343,200
+174,500
+103% +$10.5M ﹤0.01% 1710
2025
Q3 		$10.9M Sell
168,700
-30,800
-15% -$1.77M ﹤0.01% 2310
2025
Q2 		$9.7M Sell
199,500
-31,300
-14% -$1.21M ﹤0.01% 2184
2025
Q1 		$7.85M Buy
230,800
+119,800
+108% +$5.08M ﹤0.01% 2301
2024
Q4 		$4.37M Sell
111,000
-20,600
-16% -$973K ﹤0.01% 2854
2024
Q3 		$6.18M Buy
131,600
+77,100
+141% +$3.91M ﹤0.01% 2527
2024
Q2 		$2.94M Sell
54,500
-133,500
-71% -$7.72M ﹤0.01% 3839
2024
Q1 		$12.8M Buy
188,000
+19,100
+11% +$1.37M ﹤0.01% 1574
2023
Q4 		$10.6M Buy
168,900
+60,000
+55% +$3.32M ﹤0.01% 1886
2023
Q3 		$4.94M Sell
108,900
-11,500
-10% -$594K ﹤0.01% 2630
2023
Q2 		$6.76M Buy
120,400
+84,700
+237% +$4.81M ﹤0.01% 2342
2023
Q1 		$1.61M Sell
35,700
-57,100
-62% -$2.77M ﹤0.01% 4187
2022
Q4 		$3.77M Sell
92,800
-115,100
-55% -$6.11M ﹤0.01% 2871
2022
Q3 		$13.6M Sell
207,900
-68,300
-25% -$4.95M 0.01% 1414
2022
Q2 		$16.8M Sell
276,200
-5,200
-2% -$306K 0.01% 1254
2022
Q1 		$17.7M Sell
281,400
-106,400
-27% -$6.68M 0.01% 1373
2021
Q4 		$29.4M Buy
387,800
+7,500
+2% +$655K 0.01% 932
2021
Q3 		$42.6M Sell
380,300
-121,300
-24% -$15.2M 0.02% 673
2021
Q2 		$81.2M Buy
501,600
+18,600
+4% +$2.26M 0.03% 367
2021
Q1 		$58.9M Buy
483,000
+189,900
+65% +$28.7M 0.03% 431
2020
Q4 		$44.9M Buy
293,100
+147,800
+102% +$17.5M 0.02% 485
2020
Q3 		$12.2M Buy
145,300
+31,100
+27% +$2.76M 0.01% 1088
2020
Q2 		$8.39M Buy
114,200
+101,700
+814% +$5.95M 0.01% 1325
2020
Q1 		$530K Buy
12,500
+5,800
+87% +$299K ﹤0.01% 3572
2019
Q4 		$408K Buy
+6,700
New +$366K ﹤0.01% 3925

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jane Street's CRSP Position: Q2 2025 in Review

Jane Street sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 237,128 shares — an estimated $9.18M sold.

Jane Street first reported a position in CRSP in Q1 2018 and held it in 28 quarters. The position peaked at $66.7M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Jane Street reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jane Street sold 237,128 CRISPR Therapeutics shares in Q2 2025, an estimated $9.18M.
  • Jane Street first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 28 quarters.
  • Jane Street's CRISPR Therapeutics position peaked at $66.7M in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.